WithdrawnPhase 2NCT04713202
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
Studying Carcinoid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chandrikha Chandrasekhara
- Principal Investigator
- Chandrikha Chandrasekharan, MDUniversity of Iowa
- Intervention
- Telotristat ethyl(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04713202 on ClinicalTrials.govOther trials for Carcinoid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07087054Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenCrinetics Pharmaceuticals Inc.
- RECRUITINGNCT05756608Fibrosis in Chronic and Delayed Myocardial InfarctionUniversity of Edinburgh
- ACTIVE NOT RECRUITINGNANCT05064514Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart DiseaseQueen Mary University of London
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04993261An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid TumorsM.D. Anderson Cancer Center